early-dialysis-av-fistula-graft-surgery Enhanced therapeutic effect of bacillus Calmette-Gurin tx in non-muscle invasive bladder cancer. (HealthDay News) — For patients with non-muscle invasive ...
To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...
Mitomycin C can be a cost-effective alternative to BCG as intravesical treatment for intermediate-risk nonmuscle-invasive bladder cancer at a time when BCG is in short supply. Mitomycin C has ...
The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder ...
SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s largest independent providers of ...
Ferring Expands Growing Body of Real-World Evidence Reinforcing Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in ...
Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window "Medical ...
Please provide your email address to receive an email when new articles are posted on . 13% of patients with high-grade, high-risk nonmuscle-invasive tumors did not respond to bacillus Calmette-Guérin ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the presentation of new 36-month follow-up data from the Phase 3 study at the 24 th Annual Meeting of the Society of Urologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback